P-197: Valsartan improves the endothelial function in hypertensive patients with type 2 diabetes mellitus
Epidemiological data suggest thata type 2 Diabetes mellitus (DM) is often associated with hypertension and endothelial and platelets dysfunctions; the aim of the study was to evaluate, after twelve months of treatment with Valsartan, a potent AT1 receptor blocker, the effect on the endothelial and p...
Gespeichert in:
| Veröffentlicht in: | American journal of hypertension 2003-05, Vol.16 (S1), p.110A-110A |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 110A |
|---|---|
| container_issue | S1 |
| container_start_page | 110A |
| container_title | American journal of hypertension |
| container_volume | 16 |
| creator | Campanella, Mario Summa, Roberto Nanni, Maria Rita Stuard, Stefano Di Luzio, Virgilio |
| description | Epidemiological data suggest thata type 2 Diabetes mellitus (DM) is often associated with hypertension and endothelial and platelets dysfunctions; the aim of the study was to evaluate, after twelve months of treatment with Valsartan, a potent AT1 receptor blocker, the effect on the endothelial and platelets functions in hypertensive patients with type 2 DM. We studied in 202 patients ( age 63,6±9,7; 65% males ) with type 2 DM and essential hypertension ( stage 1 or 2 according the sixth report of the JNC VI ), non smokers, the influence of a single oral daily dose of Valsartan (160 mg.) on the levels of Von Willebrand factor (VWF), PCR and Fibrinogen ( as signs of endothelial dysfunction ), Soluble-P-Selectine (SPS) ( as signs of platelets function ); we moreover evaluated Systolic (SBP), Diastolic blood pressure (DBP), LDL-cholesterol, HDL-cholesterol and HbA1C. After 12 months 151 patients obtained a good pressure control ( < 130/80 mmHg according ADA 2001 - P |
| doi_str_mv | 10.1016/S0895-7061(03)00362-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_istex</sourceid><recordid>TN_cdi_proquest_journals_1026599119</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2712987501</sourcerecordid><originalsourceid>FETCH-LOGICAL-i669-983e5fd01ab97c44c8e51c69bc3d2649e83d6ddd148b45ef356f5703452a33cc3</originalsourceid><addsrcrecordid>eNo9j8FLwzAchYMoOKd_ghDwoodo0jRp402HOnXowCGyS0ibX1lm19Umne6_NzDx9A7v43s8hE4ZvWSUyas3mitBMirZOeUXlHKZELGHBkyljGRJIvbR4B85REfeLymlqZRsgNyUMJVd43dTe9MF02C3arv1BjwOC8DQ2HXM2pkaV31TBreORIMX2xa6AI13G8CtCQ6a4PG3CwscYoUTbJ0pIETNCurahd4fo4MqjsDJXw7R7P5uNhqTyevD4-hmQpyUiqicg6gsZaZQWZmmZQ6ClVIVJbeJTBXk3EprLUvzIhVQcSErkVGeisRwXpZ8iM522vjiqwcf9HLdd01c1IwmUijFmIoU2VHOB_jRbedWpttq031qmfFM6PHHXE-eubidP73oKf8FXFJqEA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1026599119</pqid></control><display><type>article</type><title>P-197: Valsartan improves the endothelial function in hypertensive patients with type 2 diabetes mellitus</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Campanella, Mario ; Summa, Roberto ; Nanni, Maria Rita ; Stuard, Stefano ; Di Luzio, Virgilio</creator><creatorcontrib>Campanella, Mario ; Summa, Roberto ; Nanni, Maria Rita ; Stuard, Stefano ; Di Luzio, Virgilio</creatorcontrib><description>Epidemiological data suggest thata type 2 Diabetes mellitus (DM) is often associated with hypertension and endothelial and platelets dysfunctions; the aim of the study was to evaluate, after twelve months of treatment with Valsartan, a potent AT1 receptor blocker, the effect on the endothelial and platelets functions in hypertensive patients with type 2 DM. We studied in 202 patients ( age 63,6±9,7; 65% males ) with type 2 DM and essential hypertension ( stage 1 or 2 according the sixth report of the JNC VI ), non smokers, the influence of a single oral daily dose of Valsartan (160 mg.) on the levels of Von Willebrand factor (VWF), PCR and Fibrinogen ( as signs of endothelial dysfunction ), Soluble-P-Selectine (SPS) ( as signs of platelets function ); we moreover evaluated Systolic (SBP), Diastolic blood pressure (DBP), LDL-cholesterol, HDL-cholesterol and HbA1C. After 12 months 151 patients obtained a good pressure control ( < 130/80 mmHg according ADA 2001 - P<0.005); we moreover observed statistically significant lowering of VWF ( from 136% to 98% - P<0.001 ) and Fibrinogen ( from 486 to 324 mg/dl - P<0.005 ); similar results wasn’t observed for PCR ( from 19,6 to 17,4 mg/dl )and SPS ( from 127 to 123 mg/dl ); LDL-cholesterol, HDL-cholesterol and HbA1c serum concentrations did not showed important modifications. We think that Valsartan is safety, significantly improves endothelial but not platelets function, and properly lowers blood pressure in hypertensive patients with type 2 DM without derangements of the other important metabolic parameters; furthemore we think that the improvement of the endothelial function is separated from blood pressure lowering.</description><identifier>ISSN: 0895-7061</identifier><identifier>EISSN: 1941-7225</identifier><identifier>DOI: 10.1016/S0895-7061(03)00362-5</identifier><identifier>CODEN: AJHYE6</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>diabetes mellitus ; endothelial dysfunction ; Valsartan</subject><ispartof>American journal of hypertension, 2003-05, Vol.16 (S1), p.110A-110A</ispartof><rights>Copyright Nature Publishing Group May 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Campanella, Mario</creatorcontrib><creatorcontrib>Summa, Roberto</creatorcontrib><creatorcontrib>Nanni, Maria Rita</creatorcontrib><creatorcontrib>Stuard, Stefano</creatorcontrib><creatorcontrib>Di Luzio, Virgilio</creatorcontrib><title>P-197: Valsartan improves the endothelial function in hypertensive patients with type 2 diabetes mellitus</title><title>American journal of hypertension</title><addtitle>AJH</addtitle><description>Epidemiological data suggest thata type 2 Diabetes mellitus (DM) is often associated with hypertension and endothelial and platelets dysfunctions; the aim of the study was to evaluate, after twelve months of treatment with Valsartan, a potent AT1 receptor blocker, the effect on the endothelial and platelets functions in hypertensive patients with type 2 DM. We studied in 202 patients ( age 63,6±9,7; 65% males ) with type 2 DM and essential hypertension ( stage 1 or 2 according the sixth report of the JNC VI ), non smokers, the influence of a single oral daily dose of Valsartan (160 mg.) on the levels of Von Willebrand factor (VWF), PCR and Fibrinogen ( as signs of endothelial dysfunction ), Soluble-P-Selectine (SPS) ( as signs of platelets function ); we moreover evaluated Systolic (SBP), Diastolic blood pressure (DBP), LDL-cholesterol, HDL-cholesterol and HbA1C. After 12 months 151 patients obtained a good pressure control ( < 130/80 mmHg according ADA 2001 - P<0.005); we moreover observed statistically significant lowering of VWF ( from 136% to 98% - P<0.001 ) and Fibrinogen ( from 486 to 324 mg/dl - P<0.005 ); similar results wasn’t observed for PCR ( from 19,6 to 17,4 mg/dl )and SPS ( from 127 to 123 mg/dl ); LDL-cholesterol, HDL-cholesterol and HbA1c serum concentrations did not showed important modifications. We think that Valsartan is safety, significantly improves endothelial but not platelets function, and properly lowers blood pressure in hypertensive patients with type 2 DM without derangements of the other important metabolic parameters; furthemore we think that the improvement of the endothelial function is separated from blood pressure lowering.</description><subject>diabetes mellitus</subject><subject>endothelial dysfunction</subject><subject>Valsartan</subject><issn>0895-7061</issn><issn>1941-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo9j8FLwzAchYMoOKd_ghDwoodo0jRp402HOnXowCGyS0ibX1lm19Umne6_NzDx9A7v43s8hE4ZvWSUyas3mitBMirZOeUXlHKZELGHBkyljGRJIvbR4B85REfeLymlqZRsgNyUMJVd43dTe9MF02C3arv1BjwOC8DQ2HXM2pkaV31TBreORIMX2xa6AI13G8CtCQ6a4PG3CwscYoUTbJ0pIETNCurahd4fo4MqjsDJXw7R7P5uNhqTyevD4-hmQpyUiqicg6gsZaZQWZmmZQ6ClVIVJbeJTBXk3EprLUvzIhVQcSErkVGeisRwXpZ8iM522vjiqwcf9HLdd01c1IwmUijFmIoU2VHOB_jRbedWpttq031qmfFM6PHHXE-eubidP73oKf8FXFJqEA</recordid><startdate>200305</startdate><enddate>200305</enddate><creator>Campanella, Mario</creator><creator>Summa, Roberto</creator><creator>Nanni, Maria Rita</creator><creator>Stuard, Stefano</creator><creator>Di Luzio, Virgilio</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200305</creationdate><title>P-197: Valsartan improves the endothelial function in hypertensive patients with type 2 diabetes mellitus</title><author>Campanella, Mario ; Summa, Roberto ; Nanni, Maria Rita ; Stuard, Stefano ; Di Luzio, Virgilio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i669-983e5fd01ab97c44c8e51c69bc3d2649e83d6ddd148b45ef356f5703452a33cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>diabetes mellitus</topic><topic>endothelial dysfunction</topic><topic>Valsartan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Campanella, Mario</creatorcontrib><creatorcontrib>Summa, Roberto</creatorcontrib><creatorcontrib>Nanni, Maria Rita</creatorcontrib><creatorcontrib>Stuard, Stefano</creatorcontrib><creatorcontrib>Di Luzio, Virgilio</creatorcontrib><collection>Istex</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Campanella, Mario</au><au>Summa, Roberto</au><au>Nanni, Maria Rita</au><au>Stuard, Stefano</au><au>Di Luzio, Virgilio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P-197: Valsartan improves the endothelial function in hypertensive patients with type 2 diabetes mellitus</atitle><jtitle>American journal of hypertension</jtitle><addtitle>AJH</addtitle><date>2003-05</date><risdate>2003</risdate><volume>16</volume><issue>S1</issue><spage>110A</spage><epage>110A</epage><pages>110A-110A</pages><issn>0895-7061</issn><eissn>1941-7225</eissn><coden>AJHYE6</coden><abstract>Epidemiological data suggest thata type 2 Diabetes mellitus (DM) is often associated with hypertension and endothelial and platelets dysfunctions; the aim of the study was to evaluate, after twelve months of treatment with Valsartan, a potent AT1 receptor blocker, the effect on the endothelial and platelets functions in hypertensive patients with type 2 DM. We studied in 202 patients ( age 63,6±9,7; 65% males ) with type 2 DM and essential hypertension ( stage 1 or 2 according the sixth report of the JNC VI ), non smokers, the influence of a single oral daily dose of Valsartan (160 mg.) on the levels of Von Willebrand factor (VWF), PCR and Fibrinogen ( as signs of endothelial dysfunction ), Soluble-P-Selectine (SPS) ( as signs of platelets function ); we moreover evaluated Systolic (SBP), Diastolic blood pressure (DBP), LDL-cholesterol, HDL-cholesterol and HbA1C. After 12 months 151 patients obtained a good pressure control ( < 130/80 mmHg according ADA 2001 - P<0.005); we moreover observed statistically significant lowering of VWF ( from 136% to 98% - P<0.001 ) and Fibrinogen ( from 486 to 324 mg/dl - P<0.005 ); similar results wasn’t observed for PCR ( from 19,6 to 17,4 mg/dl )and SPS ( from 127 to 123 mg/dl ); LDL-cholesterol, HDL-cholesterol and HbA1c serum concentrations did not showed important modifications. We think that Valsartan is safety, significantly improves endothelial but not platelets function, and properly lowers blood pressure in hypertensive patients with type 2 DM without derangements of the other important metabolic parameters; furthemore we think that the improvement of the endothelial function is separated from blood pressure lowering.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1016/S0895-7061(03)00362-5</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0895-7061 |
| ispartof | American journal of hypertension, 2003-05, Vol.16 (S1), p.110A-110A |
| issn | 0895-7061 1941-7225 |
| language | eng |
| recordid | cdi_proquest_journals_1026599119 |
| source | Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | diabetes mellitus endothelial dysfunction Valsartan |
| title | P-197: Valsartan improves the endothelial function in hypertensive patients with type 2 diabetes mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T09%3A14%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_istex&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P-197:%20Valsartan%20improves%20the%20endothelial%20function%20in%20hypertensive%20patients%20with%20type%202%20diabetes%20mellitus&rft.jtitle=American%20journal%20of%20hypertension&rft.au=Campanella,%20Mario&rft.date=2003-05&rft.volume=16&rft.issue=S1&rft.spage=110A&rft.epage=110A&rft.pages=110A-110A&rft.issn=0895-7061&rft.eissn=1941-7225&rft.coden=AJHYE6&rft_id=info:doi/10.1016/S0895-7061(03)00362-5&rft_dat=%3Cproquest_istex%3E2712987501%3C/proquest_istex%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1026599119&rft_id=info:pmid/&rfr_iscdi=true |